COVID-19 is an infectious respiratory disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2).

We develop novel intranasal therapeutics against COVID-19 by blocking the entry of SARS-CoV-2 into the host cell through ACE2 with CPT-101 ~ CPT-501.

Intranasal Administration with a spray to nose

  • Proven animal PoC with the disease model
  • Tested with human lung cells in vitro
  • Specifically targeting lung and heart which are vulnerable to viral infection

Patient-friendly treatment

  • Non-invasive intranasal spray
  • Portable and easily applied anytime and anywhere
  • Safe and flexible in dose intake

Commercial Potential

  • Intranasal therapy for prevention and/or treatment for early to late stages
  • Substantially cheaper to produce and administer compared to other treatment drugs (e.g., antiviral antibody drugs)
  • No special cold chain distribution system required
  • Long shelf life
  • Safe for those with pre-existing chronic diseases and elderly

Who We Are

As one of the portfolio drug development companies under Curyx Partners platform, Curyx Partners Therapeutics develops novel intranasal peptide therapeutics against COVID-19. Currently, because there is no treatment for COVID-19 available, developing effective therapeutic agent is of the highest importance at the moment. Furthermore, Curyx Partners Therapeutics has a number of innovative and commercially attractive assets to continue to target other coronavirus-related infectious diseases which, unfortunately, may continue to arise and spread in the future.

Call Us


Email Us

Our Address

Unit 805, 8/F Mirror Tower,
61 Mody Road,
Tsim Sha Tsui,
Kowloon, Hong Kong
Contact US

For Any Queries, Chat With Us

Skip to content